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Abstract: 
At the turn of the millennium, the Human Genome Project and the 
upcoming publication of the human genome sequence promised to open an 
entirely new approach to healthcare, based on the genotype of the 
individual. This approach was dubbed personalised medicine (PM). 
However, the analysis of sequencing results revealed that the complexity 
of the biological world had been underestimated. The major project of 
revolutionizing medicine through genomics requires a more sophisticated 
and multilevel understanding of living systems, which in turn demands new 
data, models and modes of intervention on humans as well as non-human 
organisms. Thus, the most advanced applications of PM involve a complex 
interweaving of biological and medical knowledge, as well as increasing 
attention to the technical systems through which data about any specific 
individual could be processed. Further, the development of PM needs to 
include consideration of several key ethical issues, ranging from privacy 
and data control to the risk that dependence on sophisticated technologies 
will widen the gap between haves and have‐nots both globally and within 
any one country.  
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Abstract 
At the turn of the millennium, the Human Genome Project and the 
upcoming publication of the human genome sequence promised to open an 
entirely new approach to healthcare, based on the genotype of the 
individual. This approach was dubbed personalised medicine (PM). 
However, the analysis of sequencing results revealed that the complexity of 
the biological world had been underestimated. The major project of 
revolutionizing medicine through genomics requires a more sophisticated 
and multilevel understanding of living systems, which in turn demands 
new data, models and modes of intervention on humans as well as non-
human organisms. Thus, the most advanced applications of PM involve a 
complex interweaving of biological and medical knowledge, as well as 
increasing attention to the technical systems through which data about any 
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specific individual could be processed. Further, the development of PM 
needs to include consideration of several key ethical issues, ranging from 
privacy and data control to the risk that dependence on sophisticated 
technologies will widen the gap between haves and have-nots both globally 
and within any one country.  
 
 
Keywords: human genome project; healthcare; personalised medicine; 
precision medicine; pharmacogenomics; data-intensive science; 
translational medicine.  
 
Key Concepts 
- Personalised medicine describes the direction medical solutions are 
expected to evolve, towards personalisation and individual tailoring of 
therapies and treatment regimes that will cut and divide through patient 
populations. The motor of this promised innovation will be genomic 
profiling techniques, of nuclear DNA but also ones of latter development 
such as proteomics, metabolomics, transcriptomics, and so on. 
- Biomedicine is an interdisciplinary space involving biological and 
medical knowledge/expertise as well as IT, where scientific knowledge 
about biological phenomena is mobilized in order to devise solutions to 
medical problems. 
- Data-intensive science describes the mode of scientific research that 
is emerging as paramount in an age characterised by the increasing 
reliance and dependence of researchers on the development of complex, 
distributed infrastructures for data sharing and analysis. 
- Postgenomics indicates efforts at creating and understanding models 
of life and disease that put genomic science and other biosciences at all 
levels of complexity in relation to each other.  
- Translational medicine indicates the fast-developing domain of 
efforts and debate aimed at improving the translatability of discoveries and 
techniques from the lab into solutions, drugs and therapies that can be 
effectively implemented at the point of healthcare delivery. 
 
MAIN TEXT WORD COUNT: 2660 
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Introduction: The Promise of Personalised Medicine (PM) 
During the twentieth century, the support received by research in 
biochemistry and genetics has been unparalleled in the life sciences, 
eventually culminating in the 3-billion, publicly funded Human Genome 
Project (Keller, 2000). The unravelling of the human genome sequence 
promised to open an entirely new approach to healthcare, which would be 
grounded on the genotype of the individual and thus beget the era of 
Personalised Medicine (PM) (Collins, 2010, Hood & Friend 2011). Indeed, 
the last decades have seen incremental successes of linkage analysis and 
positional cloning. The development of medical genetics has brought 
progress in unravelling the etiology of major genetic diseases (e.g. 
Duchenne muscular dystrophy, cystic fibrosis, Huntington disease, 
myotonic dystrophy, X-linked mental retardation) and hereditary cancer 
syndromes (e.g. retinoblastoma, neurofibromatosis, and colon, skin and 
breast cancer). Also, the genome project has stimulated the development of 
advanced technology to characterize DNA and study genes. Several 
initiatives for the development of infrastructures for genomic data sharing 
have been born since, to allow exchange of empirical data but also facilitate 
analysis of clinical situations (Merelli, Perez-Sanchez, Gesing, & D’Agostino, 
2014; Ray, 2015; Staes et al., 2009; Wang & Krishnan, 2014). A crucial 
spinoff of these activities has been the development and routinization of 
specific and reliable diagnostic tests, which in a (relatively limited) number 
of cases have considerably shortened the process it takes to come to a 
reliable diagnosis (Eisenstein, 2014; Keating & Cambrosio, 2013; Khoury, 
Evans, & Burke, 2010).  
 
Challenges Ahead 
Due to these developments, PM continues to attract major research 
funding and media attention, and yet the expectations raised by the 
promise of targeted, individualised treatments are far from being fulfilled 
(Keating & Cambrosio, 2013; Khoury et al., 2010; Laksman & Detsky, 2011; 
Longo, 2012). This is largely due to the complexity of building therapeutic 
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interventions in the absence of a robust, integrated understanding of 
biological systems and their relation to their environment. Indeed, the 
difficulties encountered in the quest to treat disease with the help of 
genetics have revealed that a vast multiplicity of biological entities, 
structures, levels of organization and their interactions with the 
environment need to be understood, so as to be able to fully exploit 
genomic techniques within healthcare (Hedgecoe, 2004; Wistuba et al, 
2011; O’Malley & Stotz, 2011). Continuing efforts in genomic research have 
also yielded widespread recognition of the need for integration with other 
domains of biomedical inquiry and a broader view over what phenomena 
are relevant to explaining and intervening on life, and organismic 
development and evolution (Stevens & Richardson, 2015). More advanced 
applications of PM thus involve a complex interweaving of biological and 
medical knowledge, as well as increasing attention to the technical systems 
through which data about any specific individual could be processed – a 
shift in the expertise required to develop medical interventions which has 
strong repercussions for the ways in which medical research is supported, 
disseminated, managed and translated into therapies. Further, PM requires 
the development of an industry of consumer genomic services, whose 
cultural and social consequences need to be assessed and which raises 
serious ethical questions ranging from privacy and data control (Lunshof, 
Church, & Prainsack, 2014) and the impact of genomic risk-based 
information (Green et al., 2013; Laksman & Detsky, 2011; Lyon, 2012), to 
the risk that dependence on sophisticated medical technologies will widen 
the gap between haves and have-nots both globally and within any one 
country.  
 
Model Systems, Functional Genomics and Epigenetics 
While often reviled as boring routine by the classical cell and molecular 
biologist favouring detailed functional study, the isolation of disease genes 
required original strategies and resourceful tinkering, large-scale 
collaboration and competition, the development of massive data analysis 
and sharing infrastructures, and data-intensive analysis and interpretation 
across several model systems (Leonelli & Ankeny, 2012; Makałowski et al., 
2014; Smith & Porter, 2014). The study of human genetic disease and non-
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human organisms has highlighted the existence of many novel genetic 
mechanisms, the impact of which could never have been conceived 
otherwise. These advances have yielded a better understanding of the 
chain of events connecting the molecular defects in genes, via the 
functional disturbances in cells and organs, to the clinical effects on the 
organism as a whole. This so-called ‘genotype–phenotype correlation’ is 
important not only in optimal patient and family counselling, but also to 
define proper groups for the evaluation of strategies for therapy and 
prevention, especially when more experimental, pharmacological and gene 
therapies come within reach. At the same time, most of the processes 
determining the genotype–phenotype correlation are still elusive, as they 
depend on complex interactions between multiple genes, different variant 
alleles of these genes, the tissues and cellular structures within which 
genes are expressed, and, last but not least, between genes, gene variants, 
and the environment – including other organisms upon which human 
health depends, among which microbes have paramount importance 
(O’Malley & Dupré, 2005). These biomedical questions are being tackled 
through of a combination of genomic information with large-scale 
miniaturization and automation. The increasing power of bioinformatics 
(databases, image processing and data interoperabilities), nanotechnology 
(the DNA chip and microfluidics devices) and automation (laboratory 
robotics) are bringing about an unprecedented scaling-up of information 
gathering, processing and interpretation. With a cost for genome 
sequencing now plummeting, the possibility of making sequencing a 
commonplace routine operation in research and care is increasingly within 
reach. The systematic description of the data in genome projects of humans 
and other organisms constitutes the first step in this broader endeavour. 
The combined results of cross-comparison of the data between different 
genes of one organism and between the genes and genomes of different 
organisms, the development of targeted and conditionally switchable 
animal models for human disease, and the large-scale parallel analysis of 
gene-expression profiles of tissues in normal versus diseased state and 
during growth and development has been seen as promise to 
fundamentally improve our diagnostic capacities. However, attempts to 
develop therapeutic routes, such as gene therapy and targeted drug 
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development, have indicated the need for more complex models of animal 
life and disease that account for emergent organizational structures other 
than genetic code in its various forms (Keating & Cambrosio, 2013; 
Laksman & Detsky, 2011; Longo, 2012; Samani, Tomaszewski, & Schunkert, 
2010). To continue developing our understanding of life, genomic 
approaches need to be related to knowledge and research from other 
domains of biology. This has become evident in the renewed attention 
garnered by areas such as epigenetics, systems medicine and multiscale 
modelling (Dupré, 2010a, 2010b; Samani et al., 2010; Wolkenhauer & 
Green, 2013).  
 
Pharmacogenomics 
The aim of the Human Genome Diversity (HGD) Project, a population-
based offspring of the Human Genome Project, was the elucidation of the 
individual variation of genes. An application of this developing 
understanding attracted a lot of attention from the biotechnology and 
pharmaceuticals industry. The study of genetic factors governing drug 
response, a field dubbed ‘pharmacogenomics’, was widely expected to lead 
to better targeted pharmacological treatments. Ill-understood differences 
in efficacy and side effects of medicine between different persons can be 
based on genetic differences in drug uptake and metabolism (Eisenstein, 
2014; Keating & Cambrosio, 2013; Longo, 2012). The discovery of these 
eventually could unlock major possibilities for more effective, individually 
tailored medical treatments. A welcome consequence could be a reduction 
of healthcare cost due to ineffective or even disadvantageous drug 
treatments, and an improvement in health care effectiveness. However, 
despite promising first successes in the development of targeted drugs, 
these have often not been lasting or consistent. Genomics have not 
translated in a one-stop shop solution for the development of next-
generation drugs and therapies, and as a result, the debate about 
translational medicine has arisen as a major concern. The issues that are 
connected to this slow coming revolution are of technical (Hicks, Wheeler, 
Plon, & Kimmel, 2011; Longo, 2012) and epistemological nature (Keating & 
Cambrosio, 2013; Laksman & Detsky, 2011), as well as ethical (Green et al., 
2013). From the technical point of view, even new generation sequencing 
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techniques are a very complex bundle of operations characterized by 
technical limitations that shape the quality of the map (see also 
Makałowski et al., 2014; Smith & Porter, 2014). These limitations, coupled 
with the sheer amount of data that are generated, have overwhelmed our 
capacities of selecting, linking and interpreting evidence of variation, and of 
maintaining standardized knowledge bases in shared databases. 
Furthermore, the variation in responses to drugs and activation of 
molecular pathways has been associated to a multiplicity of causal factors, 
which make diagnostic modelling ever more complex and daunts the 
translation of these findings to clinical solutions (Keating & Cambrosio, 
2013; Samani et al., 2010). These issues undermine expectations that the 
best successes in targeted therapy development can be replicated on a 
regular basis.  
 
Sequencing and Data Infrastructures 
The mapping of genes on a chromosome-by-chromosome basis is now 
flanked by whole-genome high-throughput sequencing methods. The 
working draft of the human genome, announced on 26 June 2000, reported 
on about 30000 human expressed genes, identified and mapped with great 
precision to specific subregional locations. For the high-quality finishing 
stage of whole-genome sequencing, a debate developed on how to best 
perform the quality control and functional annotation of these genes. The 
‘first-pass’ automated global annotation round, completed in April 2003, 
was followed by several rounds of assessment of the mapping quality, 
which were supported by the genome database GDB. The importance of 
GDB in this process exemplifies how the availability of well-curated, 
comprehensive phenotype-oriented mapping and annotation databases, 
providing not only gene maps but mapping and application data for clinical 
research, is crucial to the fruitful translation of genome knowledge into 
practical applications. Indeed, data infrastructure initiatives have 
flourished over the last decade, encompassing a wide spectrum of genomic 
data-based services, from general repositories to support for the analysis of 
individual cases (Bin Han Ong, 2015; Merelli et al., 2014; Staes et al., 2009; 
Wang & Krishnan, 2014). At the same time, the demise of GDB in 2008 
highlights how databases and related infrastructures have unclear 
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sustainability and longevity, as their operational costs are not shared 
across the community in a proportioned way and their adoption is not 
unanimous (Ribes & Bowker, 2009; Ure et al., 2009; Bastow & Leonelli, 
2010). 
 
Intellectual Property 
In the wake of the rapid advances in discovering new genes, a fierce 
debate emerged on public-versus-private aspects of our genome heritage. 
Especially in the field of the analysis of human cDNA/gene sequences and 
their comparison with other species to unravel function, major issues are 
still unresolved on how to strike the balance between, on the one hand, 
maximal scientific progress and public benefit – typically served by 
immediate public access of newly generated data – and, on the other, 
proper patent protection of intellectual property of inventions, required to 
safeguard the staggering investments to develop therapies. The existence 
of an independent international organization like the Human Genome 
Organization (HUGO) founded in 1989, which did not report directly to 
specific governments, industries or funding bodies, was an important asset 
to an unbiased international discussion. In 1992, 1996, 1997 and 2000, 
HUGO has generated policy papers on public access, patenting and related 
intellectual property issues including single-nucleotide polymorphisms 
(SNPs) and the effect of the European Directive on patenting biological 
materials (see Web Links). 
 
Genetic Services and Consumer Genomics 
Converting potential genetic services into beneficial healthcare involves 
tackling several challenges. First, the provision of requested information, 
which may be very burdensome to the applicant, needs to be properly 
embedded in expert clinical–genetic healthcare and preceded as well as 
guided by well-designed, understandable information. This requires 
additional research into the impact of genetic information and expansion of 
the professional field. Plans to implement screening programs for major 
genetic diseases, to widen the access of the public to voluntary preventive 
and therapeutic options, including lifestyle choices, increase the need to 
address politically the level of professional care provision.  There is an 
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acute need for training health care professionals at all levels on how to 
understand genomic information, make it part of professional practice and 
guide its interpretation by the general public (Samani et al., 2010). And yet, 
these hoped for developments are connected to, and depend on, the 
translation of laboratory innovations into new solutions that effectively 
make a difference for the patients. Furthermore, the public needs to be 
better supported in discerning the value, impact and limitations of genetic 
services. A matter of concern has been the proliferation of consumer 
genomics services, which profile a patient for risk factors of several 
diseases at once and reconstruct one’s genetic makeup, at a fraction of the 
cost of clinical-level alternatives. It is not clear how such information will 
impact on an individual’s life choices (Wyatt, Harris, Adams, & Kelly, 2013), 
at a time when one’s health is increasingly framed in terms of risk factors 
(Novas & Rose, 2001), and associated to prevention lifestyle options 
(Lucivero & Prainsack, 2015). Moreover, a narrative that frames the 
investigation of an individual’s genetic makeup as the reconstruction of 
one’s ancestry relies on a reductive concept of the determinants of 
individual identity (Dupré 2010a). There are also concerns around whether 
these services rely on recognized sequencing interpretations and 
functional gene variants, and the reliability of the sequencing methods 
used. 
 
Global Ethics 
An equally important question is whether society as a whole is ready to 
assimilate these changes and the associated threats of privacy 
infringements, unequal access to healthcare and selective inclusion or 
exclusion from insurance or labour opportunities. Human genetics 
research and personalized medicine have gained traction in part due to the 
expectation of accessible solutions to major health problems tailored to the 
genetic make-up of the individual. Tests are becoming increasingly 
affordable, and yet not only genomics-based discovery (Ashley et al., 2010; 
Lupski et al., 2010) diagnostics and therapeutics often relies on the 
consultation of expert panels to analyse ever more complex patient profiles 
and discuss best treatment options for a patient – clearly not something 
that everybody can afford in the same terms. Genetic counselling will be 
Page 9 of 15 eLS
For Review Only
ELS 
10 
necessary also for understanding the different degrees of reliability of the 
tests (and the linked risk of unnecessary therapeutic harm in the case of 
false positives) and the increasing number of risk factors being identified 
(Laksman & Detsky, 2011). As a result of differences in the assistance 
available in deciphering patient profiles, personalized medicine and health-
care might become increasingly unequal. Ethical questions also surround 
the conditions for handling and disclosing incidental findings that might 
occur as a result of genomic testing of a broad number of variables (Green 
et al., 2013) in the clinic but also as a result of scientific research (Lyon, 
2012). Genomic data can be very durable and predictive of individual 
profiles, and the increasing number of applications outside healthcare that 
are going to rely on this data, from ancestry services to policing through 
DNA phenotyping (e.g. Cookson, 2015) make the eventual function creep 
particularly concerning. Who is going to decide who is going to benefit 
from a genome sequencing service, under what conditions, and what 
health-care and counselling should accompany the procedure? But also, 
who should have access to the data, where should the data stored and what 
ownership and control should the patients have on their own sequencing 
data (Lunshof et al., 2014; Samani et al., 2010)? The realization of new 
healthcare options depends on resolving both the epistemological question 
of transnational medicine and the ethical and legal concerns relating to the 
role of genomics science in society. As demonstrated by the ongoing fierce 
debate on public versus private issues, commercial development in 
different Western regions and increased awareness of new forms of 
exploitation of vulnerable populations, it is indispensible to foster 
international dialogue on how to reap scientific gains on a worldwide scale 
and how to fight inequality from being reproduced in new forms.  
 
 
See also 
Commercialization of Human Genetic Research, Human Genome Project, 
Human Genome Project as a Social Enterprise, Bioinformatics, Role of the 
Human Reference Sequence in Personal Genomics, Use of Personalized 
Genomic Information and Pharmacogenetics and Pharmacogenomics 
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